IDEAYA Biosciences, Inc. (IDYA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $30.20: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.86; Below-average business quality.
IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the... Read more
Sell if holding. Engine safety override at $30.20: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.86; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 53. Score 4.8/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About IDEAYA Biosciences, Inc.
About IDEAYA Biosciences, Inc.
IDEAYA Biosciences holds a nine-candidate clinical pipeline anchored by darovasertib, a PKC inhibitor in a registration-enabling Phase 2/3 trial (OptimUM-02) in first-line metastatic uveal melanoma, with 437 patients enrolled by December 2025. The FDA granted darovasertib Breakthrough Therapy designation for neoadjuvant primary uveal melanoma in March 2025. In August 2025, Servier paid $210 million upfront for ex-U.S. commercialization rights, with up to $320 million in potential milestones and mid-teen to low-twenties royalties.
IDEAYA generates revenue from collaboration and license payments rather than product sales — the Servier upfront dominated 2025 cash inflows — with net losses of $113.7 million for 2025 and an accumulated deficit of $736.5 million at year-end. The pipeline spans four focus areas: darovasertib in combination with Pfizer's crizotinib for uveal melanoma; ADC/DDR inhibitor combinations (IDE849 partnered with Hengrui Pharma, IDE034, IDE161); MTAP pathway inhibitors including IDE397 in combination with Gilead's Trodelvy; and next-generation therapies IDE574 and IDE275. GSK notified the company in December 2025 of its intent to terminate two collaboration agreements covering IDE705 and IDE275, effective March 9, 2026. Manufacturing is outsourced to third-party contract manufacturers; the company held $1.05 billion in cash and marketable securities at December 31, 2025.
Show full overview
IDEAYA's near-term regulatory path is disproportionately tied to a single readout. The 10-K discloses that topline progression-free survival data from OptimUM-02 were expected in the first quarter of 2026, and that this data "may enable an accelerated approval filing in the United States." The company has never submitted an NDA; if OptimUM-02 fails to meet its primary endpoint or the FDA requires additional studies, the only remaining approval path depends on overall survival data from the same 437 enrolled patients — a multi-year delay that could weigh on the company's ability to sustain its clinical programs without further dilutive financing.
See also: Healthcare · Biotechnology
From IDEAYA Biosciences, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-15Recent Developments — IDEAYA Biosciences, Inc.
Latest news
- NEWS Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Panc — benzinga Jun 15, 2026 positive
- NEWS Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target — benzinga Jun 12, 2026 positive
- NEWS Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesd — benzinga Jun 9, 2026 negative
- NEWS Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket — benzinga Jun 9, 2026 neutral
- NEWS Reported Earlier, IDEAYA Biosciences Prices $300M Public Offering Of 5,555,556 Common Stock Shares And Pre-Funded Warran — benzinga Jun 9, 2026 negative
Generated 2026-06-17T08:56:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Unprofitable operations — net margin -62.2%. Quality floor flags this regardless of sector context.static
Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $30.20: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 4.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 2.86; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 53. Prior stop was $28.08. Score 4.8/10, moderate confidence.
Take-profit target: $45.92 (+52.1% upside). Prior stop was $28.08. Stop-loss: $28.08.
Quality below floor (1.5 < 4.0).
IDEAYA Biosciences, Inc. trades at a P/E of N/A (forward -7.9). TrendMatrix value score: 6.2/10. Verdict: Sell.
25 analysts cover IDYA with a consensus score of 4.2/5. Average price target: $53.
What does IDEAYA Biosciences, Inc. do?IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs...
IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the company funded primarily through an equity capital base and a $210M upfront from a Servier license for darovasertib outside the US. Nine product candidates are in clinical trials with darovasertib in Phase 2/3 uveal melanoma as the lead.